Chao-Feng Guo

Prof. Chao-Feng Guo

Xiangya Hospital Central South University, Changsha, Guangdong, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
YWYunjia Wang
Yunjia Wang
ZJZhongjing Jiang
Zhongjing Jiang
LDLinhua Deng
Linhua Deng
GZGengming Zhang
Gengming Zhang
XXXia Xu
Xia Xu
CGChao-Feng Guo
Chao-Feng Guo

28 February 2017 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
ZZZhenhai Zhou
Zhenhai Zhou
HZHongqi Zhang
Hongqi Zhang
CGChao-Feng Guo
Chao-Feng Guo
HYHonggui Yu
Honggui Yu
LWLongjie Wang
Longjie Wang
QGQiang Guo
Qiang Guo

16 May 2023 in Chinese Medical Journal
Verified
Journal Article
Open access
HZHongqi Zhang
Hongqi Zhang
GXGang Xiang
Gang Xiang
JLJiong Li
Jiong Li
SHSihan He
Sihan He
YWYunjia Wang
Yunjia Wang
CGChao-Feng Guo
Chao-Feng Guo
Background: Congenital scoliosis (CS) is a complex spinal malformation of unknown etiology with abnormal bone metabolism. Fibroblast growth factor 23 (FGF23), secreted by osteoblasts and osteocytes, can inhibit bone formation and mineralization. This research aims to investigate the relationship between CS and FGF23. Methods: We collected peripheral blood from two pairs of identical twins for methylation sequencing of the target region. FGF23 mRNA levels in the peripheral blood of CS patients and age-matched controls were measured. Receiver operator characteristic (ROC) curve analyses were conducted to evaluate the specificity and sensitivity of FGF23. The expression levels of FGF23 and its downstream factors fibroblast growth factor receptor 3 (FGFr3)/tissue non-specific alkaline phosphatase (TNAP)/osteopontin (OPN) in primary osteoblasts from CS patients (CS-Ob) and controls (CT-Ob) were detected. In addition, the osteogenic abilities of FGF23-knockdown or FGF23-overexpressing Ob were examined. Results: DNA methylation of the FGF23 gene in CS patients was decreased compared to that of their identical twins, accompanied by increased mRNA levels. CS patients had increased peripheral blood FGF23 mRNA levels and decreased computed tomography (CT) values compared with controls. The FGF23 mRNA levels were negatively correlated with the CT value of the spine, and ROCs of FGF23 mRNA levels showed high sensitivity and specificity for CS. Additionally, significantly increased levels of FGF23, FGFr3, OPN, impaired osteogenic mineralization and lower TNAP levels were observed in CS-Ob. Moreover, FGF23 overexpression in CT-Ob increased FGFr3 and OPN levels and decreased TNAP levels, while FGF23 knockdown induced downregulation of FGFr3 and OPN but upregulation of TNAP in CS-Ob. Mineralization of CS-Ob was rescued after FGF23 knockdown. Conclusions: Our results suggested increased peripheral blood FGF23 levels, decreased bone mineral density in CS patients, and a good predictive ability of CS by peripheral blood FGF23 levels. FGF23 may contribute to osteopenia in CS patients through FGFr3/TNAP/OPN pathway.

16 February 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
QSQingyang Shu
Qingyang Shu
GYGuanteng Yang
Guanteng Yang
MTMingxing Tang
Mingxing Tang
CGChao-Feng Guo
Chao-Feng Guo
ZHZhang Hong-Qi
Zhang Hong-Qi
JLJiong Li
Jiong Li

1 May 2021 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
YWYuan-Tao Wu
Yuan-Tao Wu
MTMing-Xing Tang
Ming-Xing Tang
YWYun-Jia Wang
Yun-Jia Wang
JLJiong Li
Jiong Li
YWYu-Xiang Wang
Yu-Xiang Wang
ZHZhang Hong-Qi
Zhang Hong-Qi
Background: Adolescent idiopathic scoliosis (AIS) is a disease characterized by changes in the three-dimensional structure of the spine. Studies have shown that the development of AIS might be associated with genetic, biomechanics, endocrine factors and abnormal bone or cartilage development. Methods: Blood samples collected from 301 female patients (161 females with AIS and 140 females without AIS) were used for genotyping. Forty-eight serum samples from 161 females with AIS and 40 serum samples from 140 females without AIS were subjected to enzyme-linked immunosorbent assays (ELISAs). We also evaluated 32 facet joints (18 females with AIS and 14 females without AIS from the 301 female patients) using immunohistochemistry, Western blotting, and isolation of human primary chondrocytes, among other methods. We treated the AIS primary chondrocytes with dihydrotestosterone (DHT) to verify the relationship among androgen, the androgen receptor (AR), and its downstream pathway proteins. Results: The serum androgen level in the AIS group was significantly decreased (1.94±0.09 vs. 2.284±0.103) compared with that in the non-AIS (control) group. The single nucleotide polymorphism genotyping results showed that the mutation rates of rs6259 between the AIS and control groups were significantly different (G/G genotype: 48.4% vs. 42.1%, G/A genotype: 40.4% vs. 35.7%, P<0.05). The levels of interleukin (IL)-6 and metalloproteinase (MMP)-13 were increased in the cartilage of AIS patients, and these patients also exhibited decreased AR levels. The cell experiment results showed that androgen reduced the degree of abnormal cartilage development in female AIS patients through the AR/IL-6/signal transducer and activator of transcription 3 (STAT3) signaling pathway. Conclusions: Our study provides a new perspective on the pathogenesis of AIS and indicates that decreased androgen levels in female AIS patients play a potential role in the development of AIS via the AR/IL-6/STAT3 signaling pathway.

15 March 2023 in Frontiers in Genetics
Verified
Journal Article
Open access
ZLZhuo-Tao Liang
Zhuo-Tao Liang
JLJia-Ke Li
Jia-Ke Li
JLJiong Li
Jiong Li
HTHao Tang
Hao Tang
CGChao-Feng Guo
Chao-Feng Guo
HZHong-Qi Zhang
Hong-Qi Zhang
Bone is the third most common metastatic site for all primary tumors, the common primary focus of bone metastases include breast cancer, prostate cancer, and so on. And the median survival time of patients with bone metastases is only 2–3 years. Therefore, it is urgent to develop new targets to diagnose and treat bone metastases. Based on two data sets GSE146661 and GSE77930 associated with bone metastases, it was found that 209 genes differentially expressed in bone metastases group and control group. PECAM1 was selected as hub-gene for the follow-up research after constructing protein-protein interaction (PPI) network and enrichment analysis. Moreover, q-PCR analysis verified that the expression of PECAM1 decreased in bone metastatic tumor tissues. PECAM1 was believed to be possibly related to the function of osteoclasts, we knocked down the expression of PECAM1 with shRNA in lymphocytes extracted from bone marrow nailed blood. The results indicated that sh-PECAM1 treatment could promote osteoclast differentiation, and the sh-PECAM1-treated osteoclast culture medium could significantly promote the proliferation and migration of tumor cells. These results suggested that PECAM1 may be a potential biomarker for the diagnosis and treatment of bone metastases of tumor.